LEGAL DISCLAIMER - THIS IS A PAID ADVERTISEMENT.
This is a paid advertisement from Cardiol Therapeutics, not a recommendation nor an offer to buy or sell securities. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Always do your own research.
Recent Coverage on Cardiol from Chimera Research Group:
“A Turning Point for Cardiol and its Valuation"
This new ODD status combined with the company’s promising drug solutions in the development pipeline makes Cardiol Therapeutics a potentially enticing stand-alone play all on its own.
But what really pushes Cardiol Therapeutics Inc. (NASDAQ: CRDL) into the crosshairs of a high-potential buyout hunt is Novo Nordisk’s recent US$1.1 billion dollar purchase
¹
of Cardiol’s peer comparable, Cardior Pharmaceuticals
.
At the time of acquisition, Cardior Pharmaceuticals, a privately held developer of RNA-based solutions for heart failure, was in Phase 2 clinical trial for its lead asset, CDR132L.
In comparison, Cardiol Therapeutics has two ongoing Phase 2 clinical trials evaluating CardiolRx™ in rare heart diseases, and CRD-38 in pre-clinical development for heart failure.
The Company’s novel pre-clinical product, CRD-38, is a subcutaneously administered drug formulation intended for treating heart failure.
While both Cardior and Cardiol Therapeutics offer potential treatment solutions catering to the enormous heart failure market, their formulations couldn’t be further apart.
Cardior’s CDR132L treatment solution is a “oligonucleotide” based drug that utilizes short single strands of synthetic DNA or RNA.² Cardiol Therapeutics Inc. (NASDAQ: CRDL) takes a much different approach by developing ultrapure cannabidiol formulations for treating heart diseases.
In the U.S. alone, roughly six million³ people over the age of 20 are living with heart failure. A number that’s projected to surge to eight million by 2030.
The impact of heart failure treatment on the already overburdened U.S. healthcare industry is reflected in the 1.9 million physician visits, 414,000 emergency department visits, and up to 1.2 million hospitalizations every year.
At an estimated current total price tag of $30 billion annually, the astronomical cost of treating heart failure is projected to MORE THAN DOUBLE to $69.8 BILLION by 2030.
It gets worse…
The 5-year mortality rate for patients suffering with heart failure is a dismal 53%.
Cardiol Therapeutics’ CRD-38
potential treatment for heart failure
is currently moving through pre-clinical trials,
and a promising solution couldn’t come soon enough.
With its flagship CardiolRx™ progressing though Phase 2 clinical trials, Cardiol Therapeutics Inc. (NASDAQ: CRDL) aims to provide promising effective treatments for those suffering from expensive, debilitating, and often deadly rare heart diseases.
Current treatments for recurrent pericarditis and acute myocarditis come with devastating costs considering…
Further complications stemming from acute myocarditis include heart failure, cardiogenic shock, unstable heart rhythm, cardiac arrest, and organ failure.
Currently, no FDA-approved therapies exist for acute myocarditis, leaving severe cases with drastic invasive options like pacemaker technologies and/or heart transplants
With Novo Nordisk’s acquisition of Cardior being just one of numerous recent high-profile buyouts of smaller drug development teams over the years, it’s obvious the major pharmaceutical giants are on the hunt for promising cardiovascular treatments considering…
Novo Nordisk’s large buyout sum for Cardior along with similarities between the two companies and offerings for treating heart diseases hasn’t gone unnoticed in the investment research community.
A recent independent research report by Leede Jones Gable
⁴
went so far as stating an implied market value for Cardiol Therapeutics Inc. (NASDAQ: CRDL) of US$16.14 a share, based on the value ascribed to Cardior.